Together, our research, policy analysis, program implementation, technical support and communication activities inform real-world practices to ensure the greatest positive impacts on our communities.
Abt has a long history designing and implementing projects aimed at understanding the breadth of the opioid epidemic, as well as innovations and solutions. Highlights include:
Conducting research on the extent of prescription drug misuse and doctor shopping.
Informing more effective prescribing practices by supporting the development of the Centers for Disease Control and Prevention (CDC) Guideline for Prescribing Opioids for Chronic Pain and implementation in practice.
Training doctors and nurses about buprenorphine to educate the medical community about its use in medication-assisted treatment.
Teaching the general public, providers, employers, and those in recovery about the rights of those in medication-assisted treatment.
Developing and evaluating innovative health information technology tools to support people in treatment and recovery from opioid use disorders.
Serving as thought leaders to local, federal and internal stakeholders on evidence-based drug policies.
Abt developed a strategic plan for the Massachusetts’ Health Policy Commission and has broad understanding of the opioid prevention and treatment continuum.
Abt has extensive experience conducting evaluations across the continuum of substance abuse prevention and treatment. Abt is a leader in developing and evaluating resources for clinicians to improve opioid prescribing guidelines and prescription monitoring programs, among others.
Abt has supported and evaluated the implementation of CDC guideline recommendations in health systems.
Abt has extensive experience conducting research and data analysis. Abt also recently developed measures to monitor health systems’ prescribing and patient care practices.
Abt has developed a set of measures for monitoring the implementation of the CDC guideline recommendations in clinical practice. We also developed and operated the Arrestee Drug Abuse Monitoring program.
Abt led several projects for the CDC and SAMHSA developing evidence-based resources for clinicians, health systems, and treatment programs.
Abt supported the development of the first-ever Surgeon General’s Report on Alcohol, Drugs, and Health (SGR-ADH). This report discusses the growing relationship between prescription drug misuse and heroin use, and provides evidence-based strategies for addressing the growing opioid epidemic.
Abt has evaluated a SAMHSA-HIV program by looking at opioid misuse as a precursor, along with HEP-C.
Abt assisted with the development of APPS for first responders to locate treatment and to aid individuals in reentering the community after incarceration to find care for opioid use disorders.
Abt is researching workforce programs that aim to improve employment outcomes for low-income adults who struggle with addiction and substance use disorders, including opioids.
Abt is a global leader in research, monitoring and evaluation. Harnessing rigorous methodologies—ranging from randomized experiments and rapid cycle evaluations to performance monitoring and in-depth qualitative analysis—we enable decision makers to answer hard questions and solve challenging problems. We know how to test what works, discover why it works, and provide timely evidence-based recommendations.
Prevention and Education – Abt has been at the forefront of educating primary care practitioners about buprenorphine. Shortly after the Food and Drug Administration's (FDA’s) approval of buprenorphine for the treatment of opioid use disorders in 2002, Abt supported SAMHSA in a national education program aimed at informing physicians about the availability of buprenorphine as a treatment option for opioid addiction. This contract also supported the development and production of Buprenorphine: A Guide for Nurses, which SAMHSA published in a technical assistance paper.
Research and Evaluation – Through a Department of Justice contract, Abt led an early assessment of prescription drug monitoring programs (PDMPs) to explore the feasibility of conducting a systematic evaluation of their effectiveness. Building on our knowledge of PDMPs, Abt conducted several evaluations of the effectiveness of these programs, including assessing their effects on the prescribing of opioid analgesics and other pain medications in ambulatory care settings in twenty-four states.
Policy Formulation – To support safe prescribing and to reduce adverse consequences of opioid use, CDC contracted with Abt to assist with researching and developing the opioid prescribing guideline for chronic pain. CDC issued the final guideline in March 2016.
Health Care Systems Development – Abt collaborated with the CDC on the national implementation and dissemination of CDC’s opioid-prescribing guidelines into primary care practices. For this effort, we collaborated with a diverse set of organizations across public and private sectors along with academic institutions including Kaiser Permanente Washington Health Research Institute, University of Washington, and Change Management Consultants. At the state level, the Massachusetts Health Policy Commission (HPC) commissioned a report from Abt examining opioid addiction in the Commonwealth. The report defined a set of system specifications, including considerations of financing and return on investment, provider capabilities, quality metrics, and workforce development, followed by a gap analysis between these system characteristics and current capabilities.
Communications and Dissemination – Abt supported the development of the first-ever Surgeon General’s Report on Alcohol, Drugs, and Health. This report discusses the growing relationship between prescription drug misuse and heroin use, and provides evidence-based strategies for addressing the growing opioid epidemic.
Abt Associates uses data and bold thinking to improve the quality of people’s lives worldwide. From increasing crop yields and combatting infectious disease, to ensuring safe drinking water and promoting access to affordable housing—and more—we partner with clients and communities to tackle their most complex challenges.